If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== Reasons for the development of multicellularity === Despite the fact that prokaryotic cells contained the building blocks required for multicellularity to arise, this transition did not occur for around 1500 million years after the origins of the first eukaryotic cell. Scientists have proposed two major theories for the reason that multicellularity arose so late after the appearance of life on Earth.
== Wallerian Degeneration == Main article: Wallerian degeneration Wallerian degeneration is a process that occurs after axonal injury. This is specifically in cases of axonotmesis and neurotmesis. It represents an innate immune response within the peripheral nervous system which is essential for preparation of regeneration. After the injury, the distal portion of the axon undergoes fragmentation, typically beginning within the first 1-2 days, this is then followed by disintegration of an axon and its myelin sheath. Schwann cells and macrophages play essential roles in this process by clearing axonal and myelin debris through phagocytosis; this is a process that occurs within 7 days and is completed within two weeks. This immune mediated response is essential for regeneration because myelin contains molecules that inhibit axonal regeneration. Schwann cells also contribute by releasing cytokines and chemokines that recruit macrophages and promote a regenerative environment. This is a process that allows regenerating axons to grow along pathways that are formed by Schwann cells. Efficient Wallerian degeneration is necessary for functional recovery, impaired or delayed immune responses can ultimately result in reduced regeneration and poorer clinical outcomes.
Water treatment is any process that improves the quality of water to make it appropriate for a specific end-use. The end use may be drinking, industrial water supply, irrigation, river flow maintenance, water recreation or many other uses, including being safely returned to the environment. Water treatment removes contaminants and undesirable components, or reduces their concentration so that the water becomes fit for its desired end-use. This treatment is crucial to human health and allows humans to benefit from both drinking and irrigation use. Advanced water treatment methods have been developed in recent decades due to increased concerns about new pollutants like microplastics, pharmaceuticals, and per- and polyfluoroalkyl substances (PFAS). These include advanced oxidation processes, membrane filtration, and adsorption-based techniques utilizing materials like tailored nanomaterials and activated carbon. Additionally, energy efficiency, resource recovery, and sustainability in water treatment systems are receiving more attention, especially in areas where water is scarce and environmental demands are growing.
Aisha Abubakar Abdulwahab - veterinary doctor, Police officer, First Female president of the Veterinary council of Nigeria, Assistant Inspector-General of the Nigerian Police. Lamido Yuguda - Former director general of the Securities and Exchange Commission, Deputy Governor Central Bank of Nigeria. Muhammad Sani Abdullahi - Former Kaduna State Commissioner for Budget and Planning, Deputy Governor(Economic Policy) Central Bank of Nigeria. Abdulkadir Ahmed - economist, longest serving Governor of the Central Bank of Nigeria between 1982 - 1993. Abubakar Koko - administrator, First Executive Secretary of the Federal Capital Development Authority (FCDA), Abuja, planned and executed Nigeria's new capital, Sarkin Yakin Gwandu. Bello Maitama Yusuf - GCON, former minister of interior, Commerce, Social Welfare, Youth, Sports and Culture. Abdullahi Yusuf Ribadu - Executive secretary National Universities Commission (NUC), former VC Modibbo Adama Federal University of Technology, Yola. Hamza Rafindadi Zayyad - former managing director New Nigeria Development Company, former Head Of Nigeria Privatization Committee. Shamsudeen Usman - economist, former deputy governor (operations, Financial Stability) Central Bank of Nigeria, former minister of national planning, former minister of finance, former president Nigerian Economic society, Founder Nigerian Sovereign Wealth Fund (NSIA). Nuhu Ribadu – current national security adviser and pioneer executive chairman of Nigeria's Economic and Financial Crimes Commission (EFCC).
Sources: en.wikipedia.org
==== Adverse effects ==== The most commonly reported adverse effects of nabiximol is dizziness, followed by drownsiness, fatigue, and nausea. Other adverse effects include anorexia, constipation, diarrhea, dysgeusia (taste disorder), oral ulcer, staining of tooth, upper abdominal pain, vomiting, xerostomia (dry mouth), confusion, and disorientation.
A gunshot wound to the neck can be particularly dangerous because of the high number of vital anatomical structures contained within a small space. The neck contains the larynx, trachea, pharynx, esophagus, vasculature (carotid, subclavian, and vertebral arteries; jugular, brachiocephalic, and vertebral veins; thyroid vessels), and nervous system anatomy (spinal cord, cranial nerves, peripheral nerves, sympathetic chain, brachial plexus). Gunshots to the neck can thus cause severe bleeding, airway compromise, and nervous system injury. Initial assessment of a gunshot wound to the neck involves non-probing inspection of whether the injury is a penetrating neck injury (PNI), classified by violation of the platysma muscle. If the platysma is intact, the wound is considered superficial and only requires local wound care. If the injury is a PNI, surgery should be consulted immediately while the case is being managed. Of note, wounds should not be explored on the field or in the emergency department given the risk of exacerbating the wound. Due to the advances in diagnostic imaging, management of PNI has been shifting from a "zone-based" approach, which uses anatomical site of injury to guide decisions, to a "no-zone" approach which uses a symptom-based algorithm. The no-zone approach uses a hard signs and imaging system to guide next steps. Hard signs include airway compromise, unresponsive shock, diminished pulses, uncontrolled bleeding, expanding hematoma, bruits/thrill, air bubbling from wound or extensive subcutaneous air, stridor/hoarseness, neurological deficits.
== Detection in humans == Two principal techniques have been used most often to detect levels of aflatoxin in humans, though they are not commercially available. The first method is measuring the AFB1-guanine adduct in the urine of subjects. The presence of this breakdown product indicates exposure to aflatoxin B1 during the past 24 hours. This technique measures only recent exposure, however. Due to the half-life of this metabolite, the level of AFB1-guanine measured may vary from day to day, based on diet, and it is not ideal for assessing long-term exposure. Another technique that has been used is a measurement of the AFB1-albumin adduct level in the blood serum. This approach provides a more integrated measure of exposure over several weeks or months.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.